Carlsson Axel C, Ingelsson Erik, Sundström Johan, Jesus Carrero Juan, Gustafsson Stefan, Feldreich Tobias, Stenemo Markus, Larsson Anders, Lind Lars, Ärnlöv Johan
Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
Department of Medical Sciences.
Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1226-1235. doi: 10.2215/CJN.08780816. Epub 2017 Jul 21.
Using a discovery/replication approach, we investigated associations between a multiplex panel of 80 circulating proteins associated with cardiovascular pathology or inflammation, and eGFR decline per year and CKD incidence.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used two cohorts, the Prospective Investigation of the Vasculature in Uppsala Seniors Study (PIVUS; =687, mean age of 70 years, 51% women) and the Uppsala Longitudinal Study of Adult Men (ULSAM; =360 men, mean age of 78 years), with 5-year follow-up data on eGFR. There were 231 and 206 incident cases of CKD during follow-up in the PIVUS and ULSAM studies, respectively. Proteomic profiling of 80 proteins was assessed by a multiplex assay (proximity extension assay). The assay uses two antibodies for each protein and a PCR step to achieve a high-specific binding and the possibility to measure multiple proteins in parallel, but gives no absolute concentrations.
In the discovery cohort from the PIVUS Study, 28 plasma proteins were significantly associated with eGFR decline per year, taking into account the multiple testing. Twenty of these proteins were significantly associated with eGFR decline per year in the replication cohort from the ULSAM Study after adjustment for age, sex, cardiovascular risk factors, medications, and urinary albumin-to-creatinine ratio (in order of significance: TNF-related apoptosis-inducing ligand receptor 2*, CD40L receptor, TNF receptor 1*, placenta growth factor*, thrombomodulin*, urokinase plasminogen activator surface receptor*, growth/differentiation factor 15*, macrophage colony-stimulating factor 1, fatty acid-binding protein*, cathepsin D, resistin, kallikrein 11*, C-C motif chemokine 3, proteinase-activated receptor 1*, cathepsin L, chitinase 3-like protein 1, TNF receptor 2*, fibroblast growth factor 23*, monocyte chemotactic protein 1, and kallikrein 6). Moreover, 11 of the proteins predicted CKD incidence (marked with * above). No protein consistently predicted eGFR decline per year independently of baseline eGFR in both cohorts.
Several circulating proteins involved in phosphate homeostasis, inflammation, apoptosis, extracellular matrix remodeling, angiogenesis, and endothelial dysfunction were associated with worsening kidney function. Multiplex proteomics appears to be a promising way of discovering novel aspects of kidney disease pathology.
采用发现/重复验证的方法,我们研究了与心血管病理或炎症相关的80种循环蛋白的多指标组合与每年估算肾小球滤过率(eGFR)下降及慢性肾脏病(CKD)发病率之间的关联。
设计、地点、参与者及测量方法:我们使用了两个队列,即乌普萨拉老年人群血管前瞻性研究(PIVUS;n = 687,平均年龄70岁,51%为女性)和乌普萨拉成年男性纵向研究(ULSAM;n = 360名男性,平均年龄78岁),有关于eGFR的5年随访数据。在PIVUS和ULSAM研究的随访期间,分别有231例和206例CKD新发病例。通过多重检测(邻近延伸分析)评估80种蛋白质的蛋白质组学特征。该检测对每种蛋白质使用两种抗体和一个聚合酶链反应步骤,以实现高特异性结合并能够同时测量多种蛋白质,但无法给出绝对浓度。
在PIVUS研究的发现队列中,考虑到多重检验,28种血浆蛋白与每年的eGFR下降显著相关。在ULSAM研究的重复验证队列中,经年龄、性别、心血管危险因素、药物治疗以及尿白蛋白与肌酐比值调整后,其中20种蛋白质与每年的eGFR下降显著相关(按显著性顺序排列:肿瘤坏死因子相关凋亡诱导配体受体2*、CD40L受体、肿瘤坏死因子受体1*、胎盘生长因子*、血栓调节蛋白*、尿激酶型纤溶酶原激活物表面受体*、生长/分化因子15*、巨噬细胞集落刺激因子1、脂肪酸结合蛋白*、组织蛋白酶D、抵抗素、激肽释放酶11*、C-C基序趋化因子3、蛋白酶激活受体1*、组织蛋白酶L、几丁质酶3样蛋白1、肿瘤坏死因子受体2*、成纤维细胞生长因子23*、单核细胞趋化蛋白1和激肽释放酶6)。此外,其中11种蛋白质可预测CKD发病率(以上标*标记)。在两个队列中,没有一种蛋白质能独立于基线eGFR持续预测每年的eGFR下降情况。
几种参与磷酸盐稳态、炎症、凋亡、细胞外基质重塑、血管生成和内皮功能障碍的循环蛋白与肾功能恶化有关。多重蛋白质组学似乎是发现肾脏疾病病理学新方面的一种有前景的方法。